Astellas Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPMF research report →
About the company
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets. Its diverse portfolio features prominent therapies such as XTANDI, an androgen receptor signaling inhibitor for prostate cancer, and XOSPATA, an FLT3 inhibitor targeting relapsed or refractory acute myeloid leukemia in adult patients with a specific FLT3 mutation.
- CEO
- Naoki Okamura
- IPO
- 2010
- Employees
- 14,754
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $25.35B
- P/E
- 13.22
- P/S
- 1.80
- P/B
- 2.11
- EV/EBITDA
- 6.98
- Div Yield
- 3.62%
- Gross Margin
- 76.08%
- Op Margin
- 18.92%
- Net Margin
- 13.63%
- ROE
- 17.44%
- ROIC
- 12.08%
- Revenue
- $2.15T · 12.57%
- Net Income
- $293.37B · 478.10%
- EPS
- $164.57 · 480.49%
- Op Income
- $422.34B
- FCF YoY
- 273.03%
- 52W High
- $17.85
- 52W Low
- $9.34
- 50D MA
- $14.34
- 200D MA
- $13.71
- Beta
- 0.08
- Avg Volume
- 3.83K
Get TickerSpark's AI analysis on ALPMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALPMF coverage
Recent articles, reports, and earnings notes.
No research on ALPMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALPMF report →Similar companies
Peers in the same neighborhood.